成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 49763-96-4 Chemical Structure| 49763-96-4

Structure of Stiripentol
CAS No.: 49763-96-4

Chemical Structure| 49763-96-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 49763-96-4

,{[proInfo.pro_purity]}

Stiripentol is an antiepileptic drug that can inhibit the synaptosomal uptake of GABA, increase the activation of GABAA receptors, it's also a microsomal cytochrome P450 (CYP) isoforms CYP3A4, CYP1A2, and CYP2C19 inhibitor.

Synonyms: BCX2600

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Stiripentol

CAS No. :49763-96-4
Formula : C14H18O3
M.W : 234.29
SMILES Code : CC(C)(C)C(O)/C=C/C1=CC=C(OCO2)C2=C1
Synonyms :
BCX2600
MDL No. :MFCD00869310
InChI Key :IBLNKMRFIPWSOY-FNORWQNLSA-N
Pubchem ID :5311454

Safety of Stiripentol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Raw264.7 macrophages 5 μM 24 h Impaired CT2A CM-induced macrophage migration PMC10914854
Raw264.7 macrophages 10 μM 24 h Inhibited CT2A CM-induced macrophage migration PMC10914854
HepG2 cells 10 μg/ml 24 h Stiripentol combined with siRNA mildly decreased oxalate production in HepG2 cells, suggesting that oxalate synthesis is mostly driven by LDH5 isoenzyme activity PMC6538379
HepG2 cells 5–100 μg/ml 24 h Stiripentol significantly decreased oxalate production in HepG2 cells in a dose-dependent manner PMC6538379
P3 cells 500 μM 24 h Inhibited lactate production, decreased cell respiration, and reduced cell proliferation and invasion PMC9728051
HEK293 cells 5-300 μM STP significantly inhibited the peak currents of Cav3.2, with an IC50 value of 64.35 μmol·L–1. PMC9314114
CHO cells 5-300 μM STP significantly inhibited the peak currents of Cav3.1, Cav3.2, and Cav3.3, with IC50 values of 69.16 μmol·L–1, 64.35 μmol·L–1, and 36.6 μmol·L–1, respectively. PMC9314114
HEK-293T cells 0.1 μM – 1 mM 5 s STP significantly potentiated the response to GABA, with the greatest potentiation observed at α3β3γ2L receptors. PMC2665930

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Oxalate excretion model Oral 200 mg/kg Once daily for 48 hours Stiripentol significantly decreased urine oxalate excretion in rats PMC6538379
Mice Glioblastoma model Intraperitoneal injection 150 mg/kg Every other day for 6 doses Impaired tumor growth and extended survival PMC10914854
Mice P3 tumor model Intraperitoneal injection 150 mg/kg Not specified Stiripentol treatment significantly increased mouse survival PMC9728051
Rats Low-dose pentylenetetrazol (PTZ) model and WAG/Rij rat model Intraperitoneal injection 150 mg/kg and 300 mg/kg Single administration, observed for 60 minutes STP at 300 mg/kg almost completely abolished PTZ-induced SWD and significantly reduced the cumulated duration and number of SWD in WAG/Rij rats. PMC9314114
Rats KA-induced temporal lobe epilepsy model Bath application 100 μM and 300 μM 20 minutes Stiripentol significantly increased RED duration at higher concentrations and had minimal effects on RED frequency. PMC6215509

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03196466 - Recruiting June 2019 France ... More >> AP-HP Cochin Recruiting Paris, France, 75014 Contact: Jean-Marc Treluyer, M.D., PhD ?? + 00 1 58 41 28 85 ?? jean-marc.treluyer@parisdescartes.fr Less <<
NCT02926898 Dravet Syndrome Phase 3 Active, not recruiting December 2018 United States, California ... More >> University of California San Francisco San Francisco, California, United States, 94143 United States, Colorado The Children'S Hospital Colorado Aurora, Colorado, United States, 80045 United States, Illinois Ann & Robert Lurie Children'S Hospital of Chicago Chicago, Illinois, United States, 60611 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Canada, British Columbia British Columbia Children'S Hospital Vancouver, British Columbia, Canada, V6H3V4 Canada, Quebec Centre Hospitalier Universitaire Sainte-Justine Montreal, Quebec, Canada, H3T 1C5 France Chu Amiens Picardie Service de Neurologie Pediatrique Amiens, France, 80054 CHU DE BORDEAUX Service De Pédiatrie Médicale Bordeaux, France, 33000 CHRU LILLE Centre Hospitalier Régional Universitaire De Lille 2 Lille, France, 59037 H?PITAL FEMME-MèRE-ENFANT H?pital Femme-mère-enfant Service De Neurologie Pédiatrique Lyon, France, 69500 H?pital La Timone, Service de Neurologie Pédiatrique Marseille, France, 13385 H?pital Necker Paris, France, 75743 H?pital Robert Debré Paris, France, 75743 CENTRE REFERENT DES EPILEPSIES Hopital De Hautpierre Strasbourg Cedex, France, F-67098 H?PITAL DES ENFANTS Pédiatrie Toulouse Cedex 9, France, 31059 Hopital Denfants Chru de Nancy Vandoeuvre Les Nancy Cedex, France, 54511 Germany Krankenhaus Mara Ggmbh, Epilepsiezentrum Bethel Bielefeld, Germany, 33617 Universit?tsklinikum Schleswig-Holstein, Klinik Für Neurop?diatrie Kiel, Germany, 24105 Kleinwachau S?chsisches Epilepsiezentrum Radeberg Gemeinnützige Gmbh Radeberg, Germany, 1454 Netherlands Kempenhaeghe Heeze, Netherlands, 5590 Ab Stichting Epilepsie Instellingen Nederland Zwolle, Netherlands, 8025 BV Spain Hospital Sant Joan de Déu Barcelona, Spain, 08950 Hospital Ruber Internacional Primera Planta Servicio de Neurologia Madrid, Spain, 28034 Clinica Universitaria de Navarra Pamplona, Spain, 31008 United Kingdom Institute of Neurosciences Queens Elizabeth University Glasgow, United Kingdom, G51 4TF Alder Hey Children'S Nhs Foundation Trust Liverpool, United Kingdom, L12 2AP Evelina Hospital London, United Kingdom, SE1 7EH Great Ormonnd Street Hospital For Children Nhs Foundation Trust London, United Kingdom, WC1N 3JH Less <<
NCT02607904 Epilepsy Phase 2 Enrolling by invitation August 2019 -
NCT02205931 Epilepsy Phase 4 Recruiting June 2019 United Kingdom ... More >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom, B4 6NH Contact: Shakti Agrawal, MBBS ?? 0044 1213338149 ?? shakti.agrawal@bch.nhs.uk ?? Principal Investigator: Shakti Agrawal, MBBS ?? ?? ?? Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8AE Contact: Andrew Mallick, FRCPCH ?? ?? ?? Principal Investigator: Andrew Mallick ?? ?? ?? Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Alasdair Parker, MA ?? 0044 1223 245151 ?? alasdair.parker@addenbrookes.nhs.uk ?? Principal Investigator: Alasdair Parker, MA ?? ?? ?? Lancashire Teaching Hospitals NHS Foundation Trust Recruiting Lancashire, United Kingdom Contact: Helen Basu ?? ?? Helen.Basu@lthtr.nhs.uk ?? Principal Investigator: Helen Basu ?? ?? ?? Leeds Teaching Hospital Recruiting Leeds, United Kingdom, LS1 3EX Contact: Helen McCullagh, RCPCH ?? 0044 113 243 2799 ?? h.mccullagh@nhs.net ?? Principal Investigator: Helen McCullagh, RCPCH ?? ?? ?? Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom, L12 2AP Contact: Rachel Kneen, BMBS ?? 0044 151 2525163 ?? rachel.kneen@liverpool.ac.uk ?? Principal Investigator: Rachel Kneen, BMBS ?? ?? ?? Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH Contact: Christin Eltze, MD Res ?? 0044 207 405 9200 ext 5438 ?? christin.eltze@gosh.nhs.uk ?? Principal Investigator: Christin Eltze, MD Res ?? ?? ?? St George's University Hospitals NHS Foundation Trust Recruiting London, United Kingdom Contact: Penny Fallon ?? ?? Penny.Fallon@stgeorges.nhs.uk ?? Principal Investigator: Penny Fallon ?? ?? ?? Royal Manchester Children's Hospital Recruiting Manchester, United Kingdom, M13 0JE Contact: Tim Martland, RCPCH ?? 0044 161 276 1234 ?? timothy.martland@cmft.nhs.uk ?? Principal Investigator: Tim Martland, RCPCH ?? ?? ?? The Newcastle Upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom Contact: Anita Devlin ?? ?? Anita.Devlin@nuth.nhs.uk ?? Principal Investigator: Anita Devlin ?? ?? ?? Sheffield Children's NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Archana Desurkar ?? ?? Archana.Desurkar@sch.nhs.uk ?? Principal Investigator: Archana Desurkar Less <<
NCT02607891 Epilepsy Phase 2 Recruiting August 2018 France ... More >> Not yet recruiting Elancourt, France Not yet recruiting Paris, France Not yet recruiting Rennes, France Netherlands Not yet recruiting Zwolle, Netherlands Poland Not yet recruiting Kraków, Poland Romania Not yet recruiting Bucuresti, Romania Spain Recruiting Barcelona, Spain Recruiting Madrid, Spain Recruiting Sevilla, Spain Sweden Recruiting Goteborg, Sweden Less <<
NCT01983722 Dravet Syndrome APPROVED_FOR_MARKETING - Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229, United States Less <<
NCT02239276 Dravet Syndrome|Epileptic Ence... More >>phalopathies Associated With SCN1A Mutations Less << NO_LONGER_AVAILABLE - Cook Children's Medical Center... More >>, Fort Worth, Texas, 76104, United States Less <<
NCT01835314 Dravet Syndrome NO_LONGER_AVAILABLE - Children's Hospital Colorado, ... More >>Aurora, Colorado, 80045, United States Less <<
NCT01533506 - - February 2013 United States, Minnesota ... More >> Mayo Clinic in Rochester Rochester, Minnesota, United States, 55905 Less <<
NCT05419180 Pharmacoresistant Focal Epilep... More >>sies Less << PHASE4 COMPLETED 2024-06-13 Centre de Référence Epilepsies... More >> Rares / Centre Investigation Clinique (CIC) - H?pital Necker-Enfants Malades, Paris, 75015, France Less <<
NCT06540378 Status Epilepticus COMPLETED 2025-05-24 -
NCT03866928 Healthy Volunteers PHASE1 COMPLETED 2019-04-05 ATC, Liège, Belgium

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.27mL

0.85mL

0.43mL

21.34mL

4.27mL

2.13mL

42.68mL

8.54mL

4.27mL

References

 

Historical Records

Categories